Anzeige
Meldung des Tages: Die Landkarte hat sich verändert: Myriads östlicher Durchbruch könnte Copper Mountain neu definieren

Idorsia News

Aktie
WKN:  A2DTEB ISIN:  CH0363463438 US-Symbol:  IDRSF Branche:  Biotechnologie Land:  Schweiz
4,095 CHF
-0,02 CHF
-0,49%
4,4928 € 09:40:22 Uhr
Depot/Watchlist
Marktkapitalisierung *
858,56 Mio. €
Streubesitz
55,25%
KGV
-0,58
Index-Zuordnung
-

Idorsia News

26.02.26 - GlobeNewswire
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
Ad hoc announcement pursuant to Art. 53 LR
12.02.26 - GlobeNewswire
Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
Idorsia will publish its Full Year 2025 Financial Reporting on Thursday February 26, at 07:00 CET.
06.02.26 - GlobeNewswire
Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
Allschwil, Switzerland – February 06, 2026 Idorsia Ltd (SIX: IDIA) announces the design of its FDA-​agreed Phase 3 registration program for lucerastat in Fabry disease. Building on ...
30.01.26 - GlobeNewswire
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-​in-class oral substrate reduction therapy addressing key unmet needs across the Fabry population ...
28.01.26 - GlobeNewswire
Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America
Ad hoc announcement pursuant to Art. 53 LR
12.01.26 - GlobeNewswire
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44 th Annual J.P. Morgan ...
12.01.26 - GlobeNewswire
Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease
In patients with impaired renal function or fast-​deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential ...
06.01.26 - GlobeNewswire
Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist
05.01.26 - GlobeNewswire
Idorsia’s daridorexant in women during menopausal transition age with insomnia
New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition age ...
05.01.26 - GlobeNewswire
Idorsia’s JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
Idorsia receives approval from Health Canada for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. ...
10.12.25 - GlobeNewswire
New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD
New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-​protective benefits of aprocitentan in addition to the marked reduction in blood ...
09.12.25 - GlobeNewswire
Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category
Idorsia’s dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of insomnia disorder, has been awarded the inaugural Prix Galien ...
10.11.25 - GlobeNewswire
Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load ...
05.11.25 - GlobeNewswire
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
New analysis confirms reductions in blood pressure and albuminuria by aprocitentan in patients with true resistant hypertension and high cardiovascular risk – including chronic ...
30.10.25 - GlobeNewswire
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
Ad hoc announcement pursuant to Art. 53 LR
10.10.25 - GlobeNewswire
Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR
09.10.25 - GlobeNewswire
Idorsia launches an offering of registered shares – to fund the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR
22.09.25 - GlobeNewswire
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
Allschwil, Switzerland – September 22, 2025 Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ ® (daridorexant) ...
19.09.25 - GlobeNewswire
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
Idorsia receives approval from Swissmedic for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. ...
10.09.25 - GlobeNewswire
Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025
Allschwil, Switzerland – September 10, 2025 Idorsia Ltd (SIX: IDIA) shares new analyses of daridorexant for patients with insomnia and further characterizes insomnia disorder at ...

Newssuche

Videos

newspaper
08:20 Uhr
2026 03 02 23 15 NEWSTRADING im März
Nur noch 12 Plätze für Top Newstrading Seminar am 8.3.! Infos zu den Strategien und Anmeldung unter ... Mehr »